Alt desc U.S. Department of Health & Human Services Alt descAlt desc National Institutes of Health Alt desc
Skip Over Navigation Links
Amyloid beta clusters among neurons in a mouse model

Repurposing a Cancer Treatment for Alzheimer’s Disease

NCATS support to Yale team leads to expedited clinical trial to test experimental drug as Alzheimer’s treatment.

Work with Us

NCATS pre-clinical programs and resources focus on key obstacles and inefficiencies in the translational process, overcoming bottlenecks that slow the development of new treatments for patients.

Learn more about how to access NCATS programs and expertise.

Repurposing Drugs

Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Learn more.

Find NCATS Programs & InitiativesAccess NCATS Expertise & Resources

Early-Stage Repurposing

Large-scale screening of compound libraries to identify therapeutic leads.

    Late-Stage Repurposing

    Preparing therapeutic leads for clinical testing and evaluation.

    Core Technologies

    Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.

      Drug Repurposing at NCATS

      Discoveries about the molecular basis of disease provide unprecedented opportunities to translate research findings into new medicines. However, developing a brand-new drug takes an enormous amount of time, money and effort, mainly due to bottlenecks in the therapeutic development process. Delays and barriers mean that translation of a promising molecule into an approved drug often takes more than 14 years. It is crucial to advance strategies to reduce this time frame, decrease costs and improve success rates.

      Drug repurposing is one such strategy. Many agents approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation and potential toxicity. Because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care.